AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca is currently conducting a significant clinical study titled ‘National Multicentre Non-interventional Study to Assess CRT Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia.’ The study aims to evaluate the diagnostic and treatment approaches for patients with unresectable locally advanced Non-Small Cell Lung Cancer (NSCLC) and Limited-stage Small Cell Lung Carcinoma (SCLC) in Russia, focusing on chemo-radiation therapy (CRT) patterns and short-term outcomes.
The study does not involve any new interventions but rather observes existing CRT practices in 50 major oncology centers across Russia. It aims to collect data on 2000 patients, providing insights into routine diagnostics and treatment results without introducing new treatments.
This observational study follows a cohort model with a prospective time perspective. It involves secondary data collection from existing medical records, ensuring compliance with local regulatory requirements. The study is non-interventional, focusing on real-world practices and outcomes.
The study began on March 31, 2023, with an estimated completion date of June 27, 2025. These dates are crucial for tracking the study’s progress and assessing its impact on clinical practices.
For AstraZeneca, this study could enhance its reputation as a leader in oncology research, potentially influencing its stock performance positively. Investors should note the competitive landscape in oncology, where real-world data can provide a strategic advantage.
The study is ongoing, with further updates available on the ClinicalTrials portal.